Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas

Nowadays, Tuberculosis (TB), a contagious infectious disease caused by Mycobacterium tuberculosis, is becoming again a worldwide health problem. The major causes that increase TB cases in the twenty one century are the rapid spread of multi-drug resistant strains, and TB association with the human immunodeficiency virus (HIV) infection, which started in the mid-1980s. Considering that, the development of new drugs is urgently needed or a human tragedy could happen. In this context, Translocase I, an enzyme involved in the biosynthesis of peptidoglycan, can be an important target for the development of new drugs against this disease. Considering that, the aim of the present review is to highlight a series of new promising anti-TB agents, which have been reported as Translocase I inhibitors namely Liposidomicines, Caprazamicines, Capuramicines, Pacidamicines, Mureidomicines e Napsamicines, Muraimicines, and Tunicamicines all of these structural templates isolated from Streptomyces species.